Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1984 2
1985 4
1986 3
1987 1
1988 2
1990 2
1991 5
1992 1
1993 4
1994 10
1995 2
1996 6
1997 9
1998 8
1999 8
2000 5
2001 10
2002 3
2003 9
2004 10
2005 14
2006 21
2007 26
2008 26
2009 32
2010 23
2011 27
2012 25
2013 33
2014 44
2015 39
2016 30
2017 26
2018 32
2019 27
2020 22
2021 19
2022 9
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

524 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Metastatic Gastric Carcinoma"
Page 1
Current treatment and recent progress in gastric cancer.
Joshi SS, Badgwell BD. Joshi SS, et al. CA Cancer J Clin. 2021 May;71(3):264-279. doi: 10.3322/caac.21657. Epub 2021 Feb 16. CA Cancer J Clin. 2021. PMID: 33592120 Free PMC article. Review.
Gastric cancer is not a top-10 malignancy in the United States but represents one of the most common causes of cancer death worldwide. ...Classification of gastric cancer based on molecular subtypes is providing an opportunity for personalized therapy. ...
Gastric cancer is not a top-10 malignancy in the United States but represents one of the most common causes of cancer death worldwide …
Gastric cancer.
Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Van Cutsem E, et al. Lancet. 2016 Nov 26;388(10060):2654-2664. doi: 10.1016/S0140-6736(16)30354-3. Epub 2016 May 5. Lancet. 2016. PMID: 27156933 Review.
Gastric cancer is one of the leading causes of cancer-related death worldwide. Many patients have inoperable disease at diagnosis or have recurrent disease after resection with curative intent. Gastric cancer is separated anatomically into true gastric …
Gastric cancer is one of the leading causes of cancer-related death worldwide. Many patients have inoperable disease at diagnosis or …
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H, Yu X, Li N, Kong M, Ma Z, Zhou D, Wang W, Wang H, Wang H, He K, Li Z, Lu Y, Zhang J, Zhao K, Zhang Y, Xu N, Li Z, Liu Y, Wang Y, Wang Y, Teng L. Jiang H, et al. J Immunother Cancer. 2022 Mar;10(3):e003635. doi: 10.1136/jitc-2021-003635. J Immunother Cancer. 2022. PMID: 35296556 Free PMC article. Clinical Trial.
The primary endpoint was pathological complete response (pCR) rate. Secondary endpoints included objective response rate, tumor regression grade per Becker criteria, survival and safety. ...This combination regimen might present a new option for patients with locally advan …
The primary endpoint was pathological complete response (pCR) rate. Secondary endpoints included objective response rate, tumor regre …
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M. Türeci O, et al. Ann Oncol. 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199. Ann Oncol. 2019. PMID: 31240302 Free PMC article. Clinical Trial.
The primary end point was the objective response rate [ORR: complete and partial response (PR)]; secondary end points included clinical benefit [ORR+stable disease (SD)], progression-free survival, safety/tolerability, and zolbetuximab pharmacokinetic profile. ...CO …
The primary end point was the objective response rate [ORR: complete and partial response (PR)]; secondary end points included cli …
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor YL, van de Haar J, van den Berg JG, van Sandick JW, Kodach LL, van Dieren JM, Balduzzi S, Grootscholten C, IJsselsteijn ME, Veenhof AAFA, Hartemink KJ, Vollebergh MA, Jurdi A, Sharma S, Spickard E, Owers EC, Bartels-Rutten A, den Hartog P, de Miranda NFCC, van Leerdam ME, Haanen JBAG, Schumacher TN, Voest EE, Chalabi M. Verschoor YL, et al. Nat Med. 2024 Feb;30(2):519-530. doi: 10.1038/s41591-023-02758-x. Epub 2024 Jan 8. Nat Med. 2024. PMID: 38191613 Free PMC article. Clinical Trial.
Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite recent advancements, most patients die of their disease. ...Twenty of 21 patients underwent surgery and were evaluable for secondary pathologic response and survival endpoints, …
Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite recent advancements, most patients die of t …
Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma.
Manji GA, Lee S, Del Portillo A, May M, Ana SS, Alouani E, Sender N, Negri T, Gautier K, Ge L, Fan W, Xie M, Sethi A, Schrope B, Tan AC, Park H, Oberstein PE, Shah MA, Raufi AG. Manji GA, et al. JAMA Oncol. 2023 Dec 1;9(12):1702-1707. doi: 10.1001/jamaoncol.2023.4423. JAMA Oncol. 2023. PMID: 37856106 Clinical Trial.
IMPORTANCE: Combining immune checkpoint blockade (ICB) with chemotherapy improves outcomes in patients with metastatic gastric and gastroesophageal junction (G/GEJ) adenocarcinoma; however, whether this combination has activity in the perioperative setting remains u …
IMPORTANCE: Combining immune checkpoint blockade (ICB) with chemotherapy improves outcomes in patients with metastatic gastric …
Intrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial.
van Workum F, Verstegen MHP, Klarenbeek BR, Bouwense SAW, van Berge Henegouwen MI, Daams F, Gisbertz SS, Hannink G, Haveman JW, Heisterkamp J, Jansen W, Kouwenhoven EA, van Lanschot JJB, Nieuwenhuijzen GAP, van der Peet DL, Polat F, Ubels S, Wijnhoven BPL, Rovers MM, Rosman C; ICAN collaborative research group. van Workum F, et al. JAMA Surg. 2021 Jul 1;156(7):601-610. doi: 10.1001/jamasurg.2021.1555. JAMA Surg. 2021. PMID: 33978698 Free PMC article. Clinical Trial.
OBJECTIVE: To compare an intrathoracic with a cervical anastomosis in a randomized clinical trial. DESIGN, SETTING, AND PARTICIPANTS: This open, multicenter randomized clinical superiority trial was performed at 9 Dutch high-volume hospit …
OBJECTIVE: To compare an intrathoracic with a cervical anastomosis in a randomized clinical trial. DESIGN, SETTING, AND …
Combined use of pembrolizumab and lenvatinib: A review.
Eisinger C, Muluneh B. Eisinger C, et al. J Oncol Pharm Pract. 2023 Sep;29(6):1461-1466. doi: 10.1177/10781552231178461. Epub 2023 May 25. J Oncol Pharm Pract. 2023. PMID: 37231712 Free PMC article. Review.
Data suggests that combination therapy with pembrolizumab and lenvatinib can be used first line for clear cell renal carcinoma in patients with favorable risk or intermediate/poor risk and in endometrial carcinoma as a preferred second-line regimen for recurrent …
Data suggests that combination therapy with pembrolizumab and lenvatinib can be used first line for clear cell renal carcinoma in pat …
Checkpoint blockade in esophagogastric cancer.
Cohen NA, Strong VE, Janjigian YY. Cohen NA, et al. J Surg Oncol. 2018 Jul;118(1):77-85. doi: 10.1002/jso.25116. Epub 2018 Jun 7. J Surg Oncol. 2018. PMID: 29878357 Free PMC article. Review.
There are few effective treatment options for metastatic esophagogastric adenocarcinomas after progression on second-line chemotherapy. Immune checkpoint blockade therapy is a promising treatment strategy for selected advanced esophagogastric cancer, and the PD-1 inhibitor …
There are few effective treatment options for metastatic esophagogastric adenocarcinomas after progression on second-line chemotherap …
HER2 in gastric adenocarcinoma: where do we stand today?
El Gharib K, Khoury M, Kourie HR. El Gharib K, et al. Per Med. 2022 Jan;19(1):67-78. doi: 10.2217/pme-2021-0004. Epub 2021 Dec 9. Per Med. 2022. PMID: 34881639 Review.
Aim:HER2 is a proto-oncogene expressed in 10-30% of gastric adenocarcinomas and is an ideal target for inhibition in malignancy with high recurrence and dismal survival rates. Materials & methods: A systematic search was conducted via PubMed, Google Scholar and …
Aim:HER2 is a proto-oncogene expressed in 10-30% of gastric adenocarcinomas and is an ideal target for inhibition in malignancy with …
524 results